Meeting
2022 ASCO Annual Meeting
Neoadjuvant and adjuvant capmatinib in resectable non–small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial.
Authors
Jay M. Lee
David Geffen School of Medicine at UCLA, Los Angeles, CA
Jay M. Lee , Mark M. Awad , Teddy Rassem Saliba , Nydia Caro , Hiya Banerjee , Karen Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT04926831
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8590)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8590
Abstract #
TPS8590
Poster Bd #
216a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations (METex14).
First Author: Mariana da Rocha Almeida Brandao
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2023 ASCO Breakthrough
Furmonertinib as adjuvant therapy in postoperative EGFR-mutated stage IA2-IIIA non-small cell lung cancer (NSCLC) with high-risk pathological factors.
First Author: Ziheng Wu